Innoviva (INVA) Return on Capital Employed (2011 - 2026)
Innoviva posted quarterly Return on Capital Employed of 6.34% for Q1 2026, down 601.0% year-on-year from 1.26% in Q1 2025, and down 15.34% on a QoQ basis from 7.48% in Q4 2025.
Innoviva (INVA) has 16 years of Return on Capital Employed data on file, last reported at 6.34% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 601.0% year-over-year to 6.34%; the trailing twelve-month figure through Mar 2026 stood at 6.34% (down 601.0% YoY), and the FY2025 full-year result was 11.05%, down 515.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 6.34%, down from 7.48% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 19.42% in Q1 2022 and bottomed at 2.89% in Q2 2023.
- The 5-year median for Return on Capital Employed is 7.07% (2022), against an average of 6.07%.
- The widest annual swing landed in 2022, when Return on Capital Employed tumbled 2348 bps; it then surged 1305 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 2.47% in 2022, then surged by 300 bps to 4.96% in 2023, then jumped by 51 bps to 7.49% in 2024, then slipped by 0 bps to 7.48% in 2025, then declined by 15 bps to 6.34% in 2026.
- The last three Return on Capital Employed figures came in at 6.34% (Q1 2026), 7.48% (Q4 2025), and 9.2% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 20.34% |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 6.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.34% |
| Dec 31, 2025 | 7.48% |
| Sep 30, 2025 | 9.20% |
| Jun 30, 2025 | 11.73% |
| Mar 31, 2025 | 12.35% |
| Dec 31, 2024 | 7.49% |
| Sep 30, 2024 | 7.31% |
| Jun 30, 2024 | 10.17% |
| Mar 31, 2024 | 4.86% |
| Dec 31, 2023 | 4.96% |
| Sep 30, 2023 | 4.83% |
| Jun 30, 2023 | -2.89% |
| Mar 31, 2023 | -2.70% |
| Dec 31, 2022 | -2.47% |
| Sep 30, 2022 | -1.96% |
| Jun 30, 2022 | 7.07% |
| Mar 31, 2022 | 19.42% |
| Dec 31, 2021 | 19.93% |
| Sep 30, 2021 | 21.51% |
| Jun 30, 2021 | 18.12% |
| Mar 31, 2021 | 14.26% |
| Dec 31, 2020 | 24.08% |
| Sep 30, 2020 | 34.68% |
| Jun 30, 2020 | 34.57% |
| Mar 31, 2020 | 35.87% |
| Dec 31, 2019 | 35.45% |
| Sep 30, 2019 | 38.11% |
| Jun 30, 2019 | 40.54% |
| Mar 31, 2019 | 44.17% |
| Dec 31, 2018 | 58.50% |
| Sep 30, 2018 | 74.84% |
| Jun 30, 2018 | 69.71% |
| Mar 31, 2018 | 61.31% |
| Dec 31, 2017 | 53.31% |
| Sep 30, 2017 | 44.42% |
| Jun 30, 2017 | 40.23% |
| Mar 31, 2017 | 33.10% |
| Dec 31, 2016 | 30.73% |
| Sep 30, 2016 | 24.66% |
| Jun 30, 2016 | 18.77% |
| Mar 31, 2016 | 12.47% |
| Dec 31, 2015 | 7.71% |
| Sep 30, 2015 | 3.29% |
| Jun 30, 2015 | -0.77% |
| Mar 31, 2015 | -3.74% |
| Dec 31, 2014 | -6.48% |
| Sep 30, 2014 | -7.63% |
| Jun 30, 2014 | -7.14% |
| Mar 31, 2014 | -6.13% |
| Dec 31, 2013 | -9.40% |
| Sep 30, 2013 | -15.23% |
| Jun 30, 2013 | -20.88% |
| Mar 31, 2013 | -32.09% |
| Dec 31, 2012 | -7.26% |
| Sep 30, 2012 | -5.10% |
| Jun 30, 2012 | -5.11% |
| Mar 31, 2012 | -1.13% |
| Dec 31, 2011 | -48.65% |
| Sep 30, 2011 | -36.34% |